Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 4:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 151 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hydroxychloroquine Clear all
Completed Phase 1 Interventional

Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00714181
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
hydroxychloroquine, temozolomide, TdT-mediated dUTP nick end labeling assay, western blotting, electron microscopy, high performance liquid chromatography, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, mass spectrometry, pharmacological study
Drug · Genetic · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Jun 27, 2026, 4:26 AM EDT
Recruiting Phase 3 Interventional

Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

NCT05799378
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Hackensack, New Jersey • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jun 27, 2026, 4:26 AM EDT
Completed Phase 1 Interventional

Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors

NCT01634893
View directory record Official record
Conditions
Refractory or Relapsed Solid Tumors
Interventions
Sorafenib combined with Hydroxychloroquine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Jun 27, 2026, 4:26 AM EDT
Completed Phase 2 Interventional

A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma

NCT03377179
View directory record Official record
Conditions
Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Intrahepatic
Interventions
ABC294640, Hydroxychloroquine Sulfate 200 MG
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Phoenix, Arizona • Atlanta, Georgia • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Jun 27, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Results available

Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer

NCT00726596
View directory record Official record
Conditions
Prostate Cancer
Interventions
hydroxychloroquine
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
5
States / cities
Hamilton, New Jersey • Morristown, New Jersey • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Jun 27, 2026, 4:26 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial

NCT04352946
View directory record Official record
Conditions
Prophylaxis, COVID-19, Health Care Worker, Hydroxychloroquine
Interventions
Hydroxychloroquine Pre-Exposure Prophylaxis, Placebo oral tablet
Drug
Lead sponsor
GeoSentinel Foundation
Other
Eligibility
18 Years and older
Enrollment
374 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Jun 27, 2026, 4:26 AM EDT
Terminated Phase 4 Interventional Results available

Hydroxychloroquine and Cognitive Function After Surgery

NCT03025087
View directory record Official record
Conditions
Individuals Undergoing Cardiac and General Surgery
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Duke University
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Jun 27, 2026, 4:26 AM EDT
Completed Phase 1 Interventional Results available

HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors

NCT02232243
View directory record Official record
Conditions
Solid Tumor
Interventions
Hydroxychloroquine, 200mg twice dailiy, Hydroxychloroquine, 400mg twice daily
Drug
Lead sponsor
Peng Wang, MD PhD
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Jun 27, 2026, 4:26 AM EDT
Terminated Phase 1 Interventional

Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy

NCT02414776
View directory record Official record
Conditions
Estrogen Receptor Positive Breast Cancer
Interventions
hydroxychloroquine
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Jun 27, 2026, 4:26 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies

NCT05221320
View directory record Official record
Conditions
Tumor, Solid, Gastrointestinal Cancer
Interventions
Ulixertinib, Hydroxychloroquine
Drug
Lead sponsor
BioMed Valley Discoveries, Inc
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Tucson, Arizona • San Francisco, California • Fairway, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Jun 27, 2026, 4:26 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine

NCT04353037
View directory record Official record
Conditions
Coronavirus, Corona Virus Infection
Interventions
Group 1 HCQ, Group 2 Placebo
Drug
Lead sponsor
UnitedHealth Group
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Jun 27, 2026, 4:26 AM EDT
Terminated Phase 2 Interventional Results available

Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19

NCT04336332
View directory record Official record
Conditions
SARS-CoV-2, COVID-19
Interventions
Hydroxychloroquine Sulfate + Azithromycin, Hydroxychloroquine Sulfate
Combination Product · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
5
States / cities
Livingston, New Jersey • New Brunswick, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Jun 27, 2026, 4:26 AM EDT
Not listed Phase 1Phase 2 Interventional

Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19

NCT04344457
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine, Indomethacin, Zithromax Oral Product
Drug
Lead sponsor
Perseverance Research Center, LLC
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Scottsdale, Arizona • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Jun 27, 2026, 4:26 AM EDT
Completed Phase 2 Interventional

Hydroxychloroquine vs. Clobetasol Rinse to Treat Oral Lichen Planus

NCT00102557
View directory record Official record
Conditions
Lichen Planus, Oral
Interventions
Hydroxychloroquine
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 27, 2026, 4:26 AM EDT
Completed Phase 1 Interventional

Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer

NCT04132505
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions
Binimetinib, Hydroxychloroquine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jun 27, 2026, 4:26 AM EDT
Completed Phase 1 Interventional Results available

To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer

NCT03215264
View directory record Official record
Conditions
Colorectal Cancer
Interventions
hydroxychloroquine, entinostat, regorafenib
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Jun 27, 2026, 4:26 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

NCT03598595
View directory record Official record
Conditions
Recurrent Osteosarcoma, Refractory Osteosarcoma
Interventions
Docetaxel, Gemcitabine, Hydroxychloroquine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jun 27, 2026, 4:26 AM EDT
Terminated Phase 1 Interventional

Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia

NCT02631252
View directory record Official record
Conditions
Leukemia, Acute Myelogenous
Interventions
Hydroxychloroquine, Mitoxantrone, Etoposide
Drug
Lead sponsor
Alison Sehgal, MD, MS
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Jun 27, 2026, 4:26 AM EDT
Terminated Phase 2 Interventional Results available

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).

NCT04566133
View directory record Official record
Conditions
Bile Duct Cancer, Biliary Cancer, Biliary Tract Neoplasms, Cholangiocarcinoma
Interventions
Trametinib, Hydroxychloroquine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Jun 27, 2026, 4:26 AM EDT
Completed No phase listed Observational

Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)

NCT01475149
View directory record Official record
Conditions
Antiphospholipid Syndrome, Thrombophilia Due to Antiphospholipid Antibody, Systemic Lupus Erythematosus
Interventions
Phlebotomy
Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Jun 27, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Results available

Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda

NCT01573754
View directory record Official record
Conditions
Porphyria Cutanea Tarda
Interventions
Hydroxychloroquine, Phlebotomy
Drug · Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2021
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Jun 27, 2026, 4:26 AM EDT
Completed Not applicable Interventional

Individual Patient Exposure and Response in Pediatric Lupus

NCT04358302
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Pillsy
Behavioral
Lead sponsor
Duke University
Other
Eligibility
5 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 14, 2024 · Synced Jun 27, 2026, 4:26 AM EDT
Completed Phase 1 Interventional

A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

NCT01897116
View directory record Official record
Conditions
Melanoma
Interventions
Hydroxychloroquine (HCQ), Vemurafenib (VEM)
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Jun 27, 2026, 4:26 AM EDT
Completed Phase 3 Interventional Results available

Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease

NCT04358081
View directory record Official record
Conditions
Covid-19
Interventions
HCQ, HCQ+AZT, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
7
States / cities
Fullerton, California • Los Angeles, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Jun 27, 2026, 4:26 AM EDT